Literature DB >> 26092596

Expression of cancer stem cell markers in metastatic colorectal cancer correlates with liver metastasis, but not with metastasis to the central nervous system.

Marlies Michl1, Volker Heinemann2, Andreas Jung3, Jutta Engel4, Thomas Kirchner3, Jens Neumann5.   

Abstract

INTRODUCTION: In colorectal cancer (CRC), metastatic spread is supposed to be mainly driven by tumor cells with stem cell features. Only about 1% of all CRC patients develop metastasis to the central nervous system (CNS). The present study intended to analyze the correlation between the expression of cancer stem cell markers and patterns of liver or CNS metastases.
MATERIAL AND METHODS: Immunohistochemistry for β-catenin, CD133, CD44 and the mismatch-repair markers hMLH1 and hMSH2 was applied to primary specimen of two CRC cohorts with CNS (n=29) and exclusive liver metastasis (n=36). Furthermore, mutation analysis for KRAS exon 2 and BRAF exon 15 was performed.
RESULTS: The expression of nuclear β-catenin, CD44 and CD133 was associated with the development of liver metastasis, but not of CNS metastasis. CD133 expression was absent in CRC with solitary CNS metastasis. Combination of cancer stem cell markers revealed high discriminatory power for the prediction of different patterns of distant spread. KRAS mutation was more frequently detected in patients with CNS metastasis, but the mutational status of KRAS and BRAF failed to show correlation with clinico-pathological data or the results of immunohistochemistry.
CONCLUSIONS: This study demonstrates that deregulation of Wnt/β-catenin-signaling and high-grade expression of cancer stem cell markers correlate with metastasis to the liver, but not to the CNS. These data implicate that in CRC other mechanisms than deregulation of Wnt/β-catenin-signaling and acquisition of cancer stemness are required for formation of CNS metastasis.
Copyright © 2015 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Brain metastasis; CD133; CD44; Colorectal cancer; Liver metastasis; β-Catenin

Mesh:

Substances:

Year:  2015        PMID: 26092596     DOI: 10.1016/j.prp.2015.05.006

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  7 in total

Review 1.  [Prognostic biomarkers for metastatic colorectal cancer].

Authors:  J H L Neumann
Journal:  Pathologe       Date:  2016-11       Impact factor: 1.011

2.  Construction and application of a lung cancer stem cell model: antitumor drug screening and molecular mechanism of the inhibitory effects of sanguinarine.

Authors:  Jia Yang; Zhihong Fang; Jianchun Wu; Xiaoling Yin; Yuan Fang; Fanchen Zhao; Shiguo Zhu; Yan Li
Journal:  Tumour Biol       Date:  2016-08-02

Review 3.  Advancements in Cancer Stem Cell Isolation and Characterization.

Authors:  Heena Jariyal; Chanchal Gupta; Vedika Sandeep Bhat; Jayant Ramakant Wagh; Akshay Srivastava
Journal:  Stem Cell Rev Rep       Date:  2019-12       Impact factor: 5.739

4.  Clinical Association of CD44 Expression with Proliferative Activity and Apoptotic State in Egyptian Patients Suffering from Ulcerative Colitis and Colorectal Carcinoma.

Authors:  Hoda El-Emshaty; Doaa Hassan; Mohamed El-Hemaly; Hisham Ismail
Journal:  Asian Pac J Cancer Prev       Date:  2021-11-01

Review 5.  CD133 expression correlates with clinicopathologic features and poor prognosis of colorectal cancer patients: An updated meta-analysis of 37 studies.

Authors:  Rongyong Huang; Dan Mo; Junrong Wu; Huaying Ai; Yiping Lu
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

6.  Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta-analysis.

Authors:  Lauren C Bylsma; Christina Gillezeau; Tamer A Garawin; Michael A Kelsh; Jon P Fryzek; Laura Sangaré; Kimberly A Lowe
Journal:  Cancer Med       Date:  2019-12-19       Impact factor: 4.452

7.  Biomarker alterations associated with distinct patterns of metastatic spread in colorectal cancer.

Authors:  M Michl; F Taverna; J Kumbrink; T S Schiergens; V Heinemann; J Engel; T Kirchner; Jens Neumann
Journal:  Virchows Arch       Date:  2020-12-09       Impact factor: 4.064

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.